OCI-Ly19 was derived from a germinal-center-B-cell-like diffuse large B-cell lymphoma (DLBCL), the DLBCL subtype in which, as in FL, EZH2 gain-of-function mutations are specifically found22, but since OCI-Ly19 itself is EZH2-WT it provides an opportunity to model the effect of acquiring an EZH2 mutation in the disease context. Here, EZH2 is linked to diffuse large B-cell lymphoma.